FLT3-IN-13 (compound 20) is a highly effective inhibitor targeting both topoisomerase II and FLT3 proteins in leukemic cells, with IC50 values of 2.26 μM for both. It induces cell cycle arrest at the G2/M phase, promotes apoptosis, and displays considerable anticytotoxic activity specifically against leukemia [1].

FLT3-IN-13 (compound 20) exhibits potent antiproliferative effects against HL-60 cells, with an IC50 of 0.48 ± 0.08 μM [1]. It induces cell cycle arrest at the G2/M phase (G1%: 24.76 ± 1.00, S%: 21.26 ± 1.72, G2%: 32.78 ± 2.21) and triggers apoptosis, with an early-apoptosis rate of 6.13 ± 1.20% and late-apoptosis of 13.06 ± 0.40% [1]. Furthermore, FLT3-IN-13 significantly upregulates P53, TNFα, and caspase 3/7, and increases the Bax/Bcl-2 ratio in HL-60 cells, detailing its mechanism of inducing apoptotic cell death [1].